兒童藥品市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、給藥途徑、最終用戶、地區和競爭格局分類，2021-2031年）

全球兒童藥品市場預計將從 2025 年的 1,394.6 億美元成長到 2031 年的 1,941.6 億美元，複合年成長率為 5.67%。

此細分市場涵蓋專為0至18歲嬰幼兒、兒童及青少年研發並核准的藥物製劑。推動該市場發展的主要因素是青少年慢性病和感染疾病率的上升，這使得人們迫切需要專門的治療性介入，而不是依賴成人藥物的仿單標示外用藥。此外，完善的法規結構和法律獎勵積極鼓勵製藥公司優先進行兒童臨床試驗，從而確保了適齡治療方法的持續開發平臺。

儘管取得了這些進展，醫藥產業仍面臨著與供應鏈脆弱性和生產不穩定性相關的重大挑戰，這些挑戰常常阻礙患者獲得醫療服務。這些物流問題往往導致基本藥物嚴重短缺，使脆弱的兒童患者的治療通訊協定更加複雜。為了說明這些基礎設施挑戰的嚴重性，美國衛生系統藥劑師協會 (ASHP) 報告稱，2024 年第一季出現了創紀錄的 323 種藥物短缺。如此廣泛的供不應求對該行業穩定構成嚴重威脅，並可能顯著阻礙整體市場擴張。

市場促進因素

兒童慢性病和感染疾病發生率的上升是推動全球兒童藥品市場成長的主要因素。疾病負擔的轉變促使人們對兒童獨特生理需求的醫療產品產生需求。隨著可預防感染疾病的再次出現，這種需求尤其明顯，促使醫療系統採購針對兒童的疫苗和治療藥物。例如，世界衛生組織（WHO）和美國疾病管制與預防中心（CDC）於2024年11月聯合發布的新聞稿指出，2023年全球麻疹病例數預計將增加20%，達到1,030萬例。這種流行病學的變化直接推動了工業生產，以應對這場青少年健康危機。

同時，旨在強制進行兒童臨床試驗的有利監管獎勵和立法支持正在改變藥物研發環境。監管機構已建立相關框架，鼓勵企業從仿單標示外且安全性和有效性均已得到驗證的治療方法，這一策略已顯著改善了產品的可及性。根據美國小兒科會 (AAP) 2024 年 4 月發布的報告，美國食品藥物管理局 (FDA) 在 2023 年更新了超過 75 種藥物和 35 種生物製藥的兒童標籤。這種監管壓力已轉化為大規模的商業性成功。賽諾菲在 2024 年 10 月發布的新聞稿中報告稱，疫苗銷售額達到 38.02 億歐元（較上年成長 25.5%）。這一顯著成長主要得益於新型兒童疫苗的推動。

市場挑戰

全球兒童藥品市場的擴張受到供應鏈脆弱性和生產不穩定性嚴重限制，導致產品供應不穩定，並削弱了醫療服務提供者的信心。當生產瓶頸或品管漏洞影響到關鍵的兒童製劑時，醫療機構往往被迫限制供應或採用次優的替代療法。這種營運上的不穩定性不僅危及患者的治療效果，也為製藥公司和醫療服務提供者帶來沉重的經濟負擔，迫使他們將資源用於應對庫存危機，而不是用於研發新治療方法和拓展市場。因此，缺乏可靠的適齡藥物供應阻礙了專科藥物的推廣應用，並限制了該行業的獲利潛力。

近期數據顯示，專科兒童醫療中心受到的影響尤其嚴重，凸顯了這項挑戰的嚴峻性。兒童醫院協會 (CHA) 2025 年的報告指出，兒童醫院的藥品短缺情況比一般醫療機構高出至少 25%。這種差異凸顯了兒童藥品供應鏈的結構性缺陷，製造商對特定配方藥品的短缺會導致生產中斷，進而引發大範圍的市場混亂。持續的藥品短缺迫使市場萎縮，相關人員在持續的物流中斷中努力維持基本的醫療標準。

市場趨勢

兒童特異性基因和細胞療法的加速發展正在從根本上改變市場格局，將焦點從症狀管理轉向針對罕見遺傳疾病的潛在治癒性治療。這一趨勢的標誌是，越來越多的複雜生物治療方法獲得監管機構核准，旨在糾正嬰幼兒的潛在基因缺陷，為曾經被認為無法治癒的疾病帶來了新的希望。例如，2024年11月，News-Medical.net網站的一篇報導報導，FDA已核准Keviridy上市，這是第一個用於治療芳香族L-氨基酸脫羧酶（AADC）缺乏症的基因療法。此療法直接注射到大腦。這項核准標誌著以金額為準、單劑量治療方法的臨床成功率和商業性可行性不斷提高，吸引了大量投資，並擴大了根治性兒童疾病的範圍。

同時，3D列印兒童劑型技術的進步，使得個人化給藥成為解決長期以來兒童患者體重和年齡各異，難以準確給藥。這項技術能夠按需生產適合不同年齡層的製劑，例如速溶片或咀嚼片，與傳統的成人藥物劑量調整方法相比，顯著提高了治療依從性和安全性。 2024年10月，德克薩斯農工大學宣布，研究人員已獲得美國國立衛生研究院（NIH）310萬美元的津貼，用於開發一種新型3​​D列印給藥系統，以治療兒童弓形蟲病。採用此類積層製造技術可實現精確的劑量滴定和口味掩蔽，有效滿足兒童獨特的生理和偏好需求。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球兒童藥物市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 按類型（呼吸系統疾病藥物、自體免疫疾病藥物、消化器官系統藥物、心血管系統藥物）
  • 依給藥途徑（口服、外用、注射、其他）
  • 依最終使用者（醫院、專科診所、居家醫療）分類
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美兒童藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲兒童藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區兒童藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲兒童藥物市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲兒童藥品市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球兒童藥品市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• AstraZeneca PLC
• Pfizer Inc
• Abbott Laboratories Inc
• Amgen Inc
• Novartis AG
• BioMarin Pharmaceutical Inc
• Gilead Sciences, Inc
• F. Hoffmann-La Roche AG
• Jazz Pharmaceuticals Inc
• GlaxoSmithKline Plc
• Sumitomo Pharma Co Ltd
• Johnson & Johnson
• Boehringer Ingelheim GmbH
• Sanofi SA
• Merck & Co. Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pediatric Drugs Market is projected to expand from USD 139.46 billion in 2025 to USD 194.16 billion by 2031, reflecting a compound annual growth rate of 5.67%. This sector encompasses pharmaceutical formulations that are specifically researched, developed, and authorized for use in infants, children, and adolescents aged zero to eighteen. A primary factor fueling this market is the rising incidence of chronic and infectious diseases among younger populations, which creates a critical need for specialized therapeutic interventions rather than relying on off-label adult medications. Additionally, supportive regulatory frameworks and legislative incentives are actively prompting pharmaceutical companies to prioritize pediatric clinical trials, ensuring a consistent development pipeline of age-appropriate treatments.

Despite these advancements, the industry encounters substantial obstacles related to supply chain vulnerabilities and manufacturing inconsistencies that frequently interrupt patient access to care. These logistical failures often lead to severe shortages of essential medicines, thereby complicating treatment protocols for vulnerable pediatric patients. Highlighting the magnitude of these infrastructure challenges, the American Society of Health-System Pharmacists reported a historic peak of 323 active drug shortages during the first quarter of 2024. Such pervasive scarcity issues represent a significant threat to the sector's stability and have the potential to severely inhibit overall market expansion.

Market Driver

The increasing prevalence of chronic and infectious conditions among children serves as a primary engine for growth within the Global Pediatric Drugs Market. As the burden of disease evolves, there is a heightened requirement for medical formulations that specifically cater to the unique physiological needs of pediatric patients. This necessity is particularly visible regarding the resurgence of preventable infectious diseases, which drives healthcare systems to acquire targeted pediatric immunizations and therapeutics. For instance, a November 2024 press release from the World Health Organization and the U.S. Centers for Disease Control and Prevention noted that worldwide measles cases surged by 20% to an estimated 10.3 million in 2023, an epidemiological shift that directly spurs industrial production to manage health crises in younger demographics.

Simultaneously, the development landscape is being transformed by favorable regulatory incentives and legislative support aimed at mandating pediatric-specific clinical trials. Regulatory authorities have established frameworks that urge companies to shift away from off-label prescribing toward approved therapies that guarantee safety and efficacy, a strategy that is producing tangible improvements in product availability. According to an April 2024 report by the American Academy of Pediatrics, the FDA updated the labeling of over 75 drugs and 35 biologics with pediatric information throughout 2023. This regulatory pressure translates into significant commercial success, as evidenced by Sanofi's October 2024 press release, which reported €3,802 million in vaccine sales-a 25.5% increase attributed largely to novel pediatric immunizations.

Market Challenge

The expansion of the Global Pediatric Drugs Market is severely hampered by supply chain fragilities and manufacturing inconsistencies, which result in unpredictable product availability and diminished confidence among healthcare providers. When production bottlenecks or quality control failures impact essential pediatric formulations, medical facilities are often forced to ration supplies or rely on less optimal therapeutic alternatives. This operational volatility not only endangers patient outcomes but also imposes significant financial strains on pharmaceutical entities and healthcare providers, compelling them to divert resources toward managing inventory crises instead of developing new treatments or expanding market reach. Consequently, the inability to ensure a reliable supply of age-appropriate medications deters the adoption of specialized drugs and restricts the sector's revenue potential.

The gravity of this challenge is emphasized by recent data highlighting the disproportionate impact on specialized pediatric care centers. According to the Children's Hospital Association in 2025, pediatric hospitals encountered at least 25% more drug shortages compared to general healthcare facilities. This disparity underscores the inherent weakness of the pediatric supply chain, where a scarcity of manufacturers for niche formulations can precipitate widespread market disruption during production failures. Such persistent shortages force the market to contract, as stakeholders struggle to uphold basic standards of care in the face of continuing logistical breakdowns.

Market Trends

The market landscape is being fundamentally altered by the acceleration of pediatric-specific gene and cell therapies, which are shifting the focus from symptomatic management to potential cures for rare genetic disorders. This trend is defined by an increase in regulatory approvals for complex biological treatments engineered to rectify underlying genetic defects in infants and children, providing new hope for conditions that were once considered untreatable. For example, a November 2024 article from News-Medical.net highlighted the FDA approval of Kebilidi, the first gene therapy for aromatic L-amino acid decarboxylase (AADC) deficiency, which is administered directly into the brain. This approval illustrates the growing clinical success and commercial viability of high-value, one-time curative therapies that are attracting substantial investment and broadening the range of treatable pediatric indications.

In parallel, the advancement of 3D-printed pediatric dosage forms for personalized dosing is emerging as a vital solution to the persistent difficulty of administering accurate doses to children of diverse weights and ages. This technology facilitates the on-demand production of age-appropriate formulations, such as rapidly dissolving tablets or chewables, thereby significantly enhancing treatment adherence and safety compared to the traditional method of manipulating adult medications. As reported by Texas A&M University in October 2024, researchers received a $3.1 million grant from the National Institutes of Health to create novel 3D-printed delivery systems for treating pediatric toxoplasmosis. The implementation of such additive manufacturing techniques permits precise titration and taste-masking, effectively addressing the specific physiological and preference-based requirements of the pediatric demographic.

Key Market Players

• AstraZeneca PLC
• Pfizer Inc
• Abbott Laboratories Inc
• Amgen Inc
• Novartis AG
• BioMarin Pharmaceutical Inc
• Gilead Sciences, Inc
• F. Hoffmann-La Roche AG
• Jazz Pharmaceuticals Inc
• GlaxoSmithKline Plc
• Sumitomo Pharma Co Ltd
• Johnson & Johnson
• Boehringer Ingelheim GmbH
• Sanofi SA
• Merck & Co. Inc

Report Scope

In this report, the Global Pediatric Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pediatric Drugs Market, By Type

• Respiratory Disorder Drugs
• Autoimmune Disorder Drugs
• Gastrointestinal Drugs
• Cardiovascular Drugs

Pediatric Drugs Market, By Route Of Administration

• Oral
• Topical
• Parenteral
• Others

Pediatric Drugs Market, By End User

• Hospitals
• Specialty Clinics
• Homecare

Pediatric Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pediatric Drugs Market.

Available Customizations:

Global Pediatric Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pediatric Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Respiratory Disorder Drugs, Autoimmune Disorder Drugs, Gastrointestinal Drugs, Cardiovascular Drugs)
  • 5.2.2. By Route Of Administration (Oral, Topical, Parenteral, Others)
  • 5.2.3. By End User (Hospitals, Specialty Clinics, Homecare)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Pediatric Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Route Of Administration
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pediatric Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Route Of Administration
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Pediatric Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Route Of Administration
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Pediatric Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Route Of Administration
      • 6.3.3.2.3. By End User

7. Europe Pediatric Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Route Of Administration
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pediatric Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Route Of Administration
      • 7.3.1.2.3. By End User
  • 7.3.2. France Pediatric Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Route Of Administration
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Pediatric Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Route Of Administration
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Pediatric Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Route Of Administration
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Pediatric Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Route Of Administration
      • 7.3.5.2.3. By End User

8. Asia Pacific Pediatric Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Route Of Administration
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pediatric Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Route Of Administration
      • 8.3.1.2.3. By End User
  • 8.3.2. India Pediatric Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Route Of Administration
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Pediatric Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Route Of Administration
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Pediatric Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Route Of Administration
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Pediatric Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Route Of Administration
      • 8.3.5.2.3. By End User

9. Middle East & Africa Pediatric Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Route Of Administration
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pediatric Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Route Of Administration
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Pediatric Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Route Of Administration
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Pediatric Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Route Of Administration
      • 9.3.3.2.3. By End User

10. South America Pediatric Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Route Of Administration
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pediatric Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Route Of Administration
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Pediatric Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Route Of Administration
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Pediatric Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Route Of Administration
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pediatric Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer Inc
• 15.3. Abbott Laboratories Inc
• 15.4. Amgen Inc
• 15.5. Novartis AG
• 15.6. BioMarin Pharmaceutical Inc
• 15.7. Gilead Sciences, Inc
• 15.8. F. Hoffmann-La Roche AG
• 15.9. Jazz Pharmaceuticals Inc
• 15.10. GlaxoSmithKline Plc
• 15.11. Sumitomo Pharma Co Ltd
• 15.12. Johnson & Johnson
• 15.13. Boehringer Ingelheim GmbH
• 15.14. Sanofi SA
• 15.15. Merck & Co. Inc

16. Strategic Recommendations

17. About Us & Disclaimer